drugset
drugset / Trial / NCT03453034

Tolerance and Pharmacokinetics of TQ-B3233

NCT03453034 ↗

Phase 1 Unknown 50 enrolled Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
NaSingle-groupOpen-labelOther

Summary

Study of Tolerance and Pharmacokinetics of TQ-B3233 Capsule, phase I,single arm.

Timeline

Start
2017-11-22
Primary completion
2018-12-31
Completion
2018-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject TQ-B3233 Unknown — —

Indications

neoplasm